Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04725812
Other study ID # STUDY00000039
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date September 13, 2021
Est. completion date December 7, 2021

Study information

Verified date November 2023
Source Cedars-Sinai Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase II, single arm, open-label study to determine if treatment with eculizumab prolongs pregnancy compared to historical controls in women with preeclampsia between 23-30 weeks gestation.


Description:

The purpose of this study is to determine if eculizumab is an effective treatment to prolong pregnancy in women with preeclampsia, compared to a historical control group of women that received standard of care alone. Eligible subjects will be women with preeclampsia before 30 weeks gestation, who have been deemed suitable for prolongation of pregnancy. The primary research procedure is administration of the study drug, eculizumab, by intravenous infusions weekly for four weeks, then every other week. Eculizumab is approved by the FDA for the treatment of women with atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria and is frequently used in pregnant women with these disorders. However, eculizumab is considered investigational in this study because it has not been approved by the FDA for use in patients with preeclampsia. Subject participation will last approximately 8-12 weeks on average, and the study drug will be continued until 48 hours after delivery in the treatment arm. All subjects will be followed at 2 weeks and 6 weeks after delivery to assess maternal and neonatal outcomes. A later visit may be required to complete the meningococcal vaccine schedule. The investigators believe that eculizumab will prolong pregnancy in women with preeclampsia diagnosed before 30 weeks gestation with overactive complement. As there is no effective treatment for preeclampsia other than delivery currently, women with preeclampsia before 30 weeks gestation are managed using a "watch and wait" approach (i.e., expectant management). Due to the unpredictable nature of preeclampsia, expectant management places mother and child at significant risk until delivery occurs. Eculizumab may be an improvement over current standard of care as it provides a treatment option for patients who would otherwise be managed with expectant management alone. If the study aims are achieved, eculizumab will emerge as an effective treatment option for women with preeclampsia.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date December 7, 2021
Est. primary completion date December 7, 2021
Accepts healthy volunteers No
Gender Female
Age group 13 Years and older
Eligibility Inclusion criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures & availability for study duration 3. Biologically female, aged =13, body weight =40kg 4. Diagnosed with preeclampsia between 23-29+6/7 weeks gestation, by following criteria: 1. Blood pressure =160 mmHg systolic or =110 mmHg diastolic OR 2. Blood pressure =140 mmHg systolic or =90 mmHg diastolic and at least one of the following i. Proteinuria (spot protein/creatinine =0.3mg/mg or 24Hr protein =300 mg) ii. Platelet count <100,000/µl iii. Aspartate or alanine transaminase >2x upper limit of normal iv. Creatinine >1.1 mg/dl or oliguria v. Pulmonary edema 5. Ability to take intravenous medication and be willing to adhere to the eculizumab regimen 6. Ability to receive meningococcal vaccine and be willing to adhere to antibiotic regimen Exclusion Criteria: An individual who meets any of the following criteria prior to enrollment will be excluded from participation in this study: 1. Known allergic reactions eculizumab or meningococcal vaccine 2. Febrile illness within prior 2 weeks 3. Treatment with another investigational drug within previous 6 months 4. Inpatient expectant management for preeclampsia >72 hours prior to enrollment 5. Fetal contraindication to expectant management of pregnancy 6. Platelet count <50,000/µl 7. Diagnosis of hemolysis, elevated liver enzymes, low platelet count (HELLP) syndrome - Must meet all of the following criteria to be excluded: LDH >600 U/L, platelet count < 100,000/µl, AST >2x upper limit of normal, ALT >2x upper limit of normal 8. Diagnosis of Eclampsia 9. Diagnosis of Placental abruption 10. Intrauterine fetal demise 11. Coagulopathy (INR = 1.5) 12. Fibrinogen <200 mg/dl 13. Persistent, severe headache unresponsive to medications 14. Persistent, severe visual disturbances 15. Persistent, severe epigastric or RUQ pain unresponsive to medications 16. Diagnosis of Systemic lupus erythematosus 17. Diagnosis of Anti-phospholipid antibody syndrome 18. Diagnosis of Atypical hemolytic uremic syndrome 19. Diagnosis of Paroxysmal nocturnal hemoglobinuria 20. Known complement deficiency 21. Diagnosis of Venous thromboembolism active or within 6 months of enrollment 22. Diagnosis of Human immunodeficiency virus (HIV) 23. Diagnosis of Hepatitis C virus (active viremia) 24. Diagnosis of Cancer (not in remission) 25. History of Solid organ transplant 26. Systemic viral or bacterial infection (active, untreated) 27. Active use of eculizumab at time of enrollment 28. Contraindication to eculizumab treatment or complement system blockade 29. Contraindication to meningococcal vaccine 30. Body weight <40kg 31. Age <13 32. Neutropenia (<1500/mm3) 33. Gonorrhea, chlamydia, or syphilis in current pregnancy 34. Illicit substance use in current pregnancy 35. Currently homeless or incarcerated 36. Alcoholism 37. Liver cirrhosis 38. Insulin dependent diabetes 39. Active use of immunosuppressive therapies, other than use of corticosteroids for fetal lung maturity 40. Use of prophylactic or therapeutic heparin, or low molecular weight heparin, in pregnancy for hypercoagulable condition

Study Design


Intervention

Drug:
Eculizumab
Eculizumab Intravenous Solution

Locations

Country Name City State
United States Cedars-Sinai Medical Center Los Angeles California

Sponsors (2)

Lead Sponsor Collaborator
Cedars-Sinai Medical Center Alexion Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Latency (in Days) From Enrollment to Delivery The difference in mean number of days (latency) from enrollment in the study (or hospital admission for controls) to delivery between participant receiving eculizumab compared to historical controls.
For treatment-arm participants latency is determined from enrollment to delivery.
For historical controls latency is determined from hospital admission (or initial diagnosis for controls hospitalized for other indication) for preeclampsia until delivery.
Subjects and historical controls all defined as women with preeclampsia between 23-30 weeks gestation.
24 months
Secondary Composite Adverse Maternal Outcomes The difference in the composite number of adverse maternal outcomes between subjects receiving eculizumab compared to historical controls
•Adverse maternal outcomes directly attributed to preeclampsia defined as the following: syndrome of hemolysis, elevated liver enzyme, and low platelet count (HELLP), eclampsia, placental abruption, stroke, venous thrombosis or pulmonary embolism, pulmonary edema, posterior reversible encephalopathy syndrome, postpartum hemorrhage (>1000 cc), blood transfusion, admission to the intensive care unit, acute kidney injury, acute tubular necrosis, dialysis, or death
24 months
Secondary Composite Adverse Neonatal Outcomes The difference in the composite number of adverse neonatal outcomes between subjects receiving eculizumab compared to historical controls.
•Adverse neonatal outcomes directly attributable to preeclampsia or indirectly attributable due to preterm delivery due to preeclampsia defined as the following: Respiratory distress syndrome, bronchopulmonary dysplasia, intraventricular hemorrhage, retinopathy of prematurity, necrotizing enterocolitis, seizure, hypoxic-ischemic encephalopathy, metabolic acidosis, infection, sepsis, previously unrecognized major malformation detected at birth, patent ductus arteriosus requiring indomethacin, or death.
24 months
Secondary Changes in Blood and Urine Concentrations of Terminal Complement Protein C5a Before and After Each Treatment. The Difference in the concentration of C5a in blood and urine, before treatment ( ex. visit day 1) compared to after treatment in each participant receiving eculizumab.
•Concentrations of C5a in blood and urine will be determined by enzyme linked immunosorbent assays (ELISA).
24 months
Secondary Changes in Blood and Urine Concentrations of Terminal Complement Protein C5b-9 Before and After Each Treatment. The difference in blood and urine concentrations of C5b-9, before treatment ( ex. visit day 1) compared to after treatment in each participant receiving eculizumab. 24 months
Secondary Changes in Blood and Urine Concentrations of Complement Protein CD59 Before and After Each Treatment. The difference in blood and urine concentrations of CD59, before treatment ( ex. visit day 1) compared to after treatment in each participant receiving eculizumab. 24 months
Secondary Aspartate and Alanine Transaminase Concentration Before and After Each Treatment. Differences in the concentration of aspartate and alanine transaminase (U/L) will be compared before treatment (ex. visit day 1) and after treatment in each participant receiving eculizumab. 24 months
Secondary Hemoglobin Concentration Before and After Each Treatment. Differences in the concentrations of measures of hemoglobin will be compared before treatment (ex. visit day 1) and after treatment in each participant receiving eculizumab. 24 months
Secondary Platelet Count Before and After Each Treatment. Differences in the platelet count will be compared before treatment (ex. visit day 1) and after treatment in each participant receiving eculizumab. 24 months
Secondary Lactate Dehydrogenase Concentration Before and After Each Treatment. Differences in the concentration of serum lactate dehydrogenase will be compared before treatment (ex. visit day 1) and after treatment in each participant receiving eculizumab. 24 months
Secondary Serum Creatinine Before and After Each Treatment. Differences in the concentration of serum creatinine will be compared before treatment (ex. visit day 1) and after treatment in each participant receiving eculizumab. 24 months
Secondary Urine Protein Concentration Before and After Each Treatment. Differences in urine protein concentration will be compared before treatment (ex. visit day 1) and after treatment in each participant receiving eculizumab. 24 months
Secondary Ratio of Urine Protein to Urine Creatinine Before and After Each Treatment. Differences in the ratio of urine protein concentration to urine creatinine concentration will be compared before treatment (ex. visit day 1) and after treatment in each participant receiving eculizumab. 24 months
Secondary Serum Concentration of Soluble Fms-like Tyrosine Kinase 1 (sFlt-1) Before and After Each Treatment. Differences in the concentration of soluble fms-like tyrosine kinase 1 (sFlt-1) will be compared before treatment (ex. visit day 1) and after treatment in each participant receiving eculizumab. 24 months
Secondary Serum Concentration of Placental Growth Factor (PlGF) Before and After Each Treatment. Differences in the concentration of placental growth factor (PlGF) will be compared before treatment (ex. visit day 1) and after treatment in each participant receiving eculizumab. 24 months
Secondary Serum Ratio of Soluble Fms-like Tyrosine Kinase 1 (sFlt-1) Concentration to Placental Growth Factor (PlGF) Concentration (sFlt-1/PlGF) Before and After Each Treatment. Differences in the serum ratio of soluble fms-like tyrosine kinase 1 (sFlt-1) concentration to placental growth factor (PlGF) concentration (sFlt-1/PlGF) will be compared before treatment (ex. visit day 1) and after treatment in each participant receiving eculizumab. 24 months
Secondary Serious Adverse Events Assessment of serious adverse events in eculizumab treatment arm compared with historical controls.
Neisseria meningitidis infection or development of invasive meningococcal disease, Neisseria gonorrhoeae, Neisseria sicca/subflava, and Neisseria spp unspecified and Aspergillus infections.
Graded clinical and laboratory abnormalities, according to the U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS; DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1. [July 2017].
24 months
See also
  Status Clinical Trial Phase
Completed NCT05017974 - Research on Improving Sleep During Pregnancy N/A
Completed NCT03284515 - Vaccination In Pregnancy Gene Signature: VIP Signature Study
Recruiting NCT05969795 - Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support Phase 1
Recruiting NCT06051201 - Innovation for Small-scale Experiments: ReceptIVFity Test N/A
Recruiting NCT04828382 - Prospective Study of Pregnancy in Women With Cystic Fibrosis
Enrolling by invitation NCT04527926 - STEPuP: Prenatal Provider Education and Training to Improve Medication-assisted Treatment Use During Pregnancy N/A
Recruiting NCT04278651 - Early Antenatal Support for Iron Deficiency Anemia Phase 4
Recruiting NCT04405700 - Measuring Adverse Pregnancy and Newborn Congenital Outcomes
Recruiting NCT06258902 - Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation
Completed NCT05487196 - Effectiveness of Clonidine, Dexmedetomidine, and Fentanyl Adjuncts for Labor Epidural Analgesia Phase 2
Completed NCT03750968 - Lutein & Zeaxanthin in Pregnancy - Carotenoid Supplementation During Pregnancy: Ocular and Systemic Effects Phase 2
Enrolling by invitation NCT06127277 - Next4You: A Fully Mobile Relationships Based Program for Youth in Foster Care N/A
Completed NCT05897697 - Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
Recruiting NCT05899101 - The Impact of Opioid and Cannabis Exposure on Fetal Growth
Completed NCT05502510 - Assessing the Effectiveness and Efficacy of the MyHealthyPregnancy Application
Completed NCT04296396 - Opioid Prescription After Cesarean Trial Phase 3
Not yet recruiting NCT06069869 - Multiple Micronutrient Supplementation (MMS) Iron Dose Acceptability Crossover Trial Phase 3
Not yet recruiting NCT06069856 - Multiple Micronutrient Supplementation (MMS) IFA- Iron Dose Acceptability Crossover Trial Phase 3
Not yet recruiting NCT06079918 - Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania Phase 3
Not yet recruiting NCT06163651 - Evaluating a One-Year Version of the Parent-Child Assistance Program N/A